MCID: ACH005
MIFTS: 51

Achalasia

Categories: Cardiovascular diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Achalasia

MalaCards integrated aliases for Achalasia:

Name: Achalasia 12 74 52 29 54 6 15 71
Esophageal Achalasia 12 52 71
Cardiospasm 12 74 52
Hypertensive Lower Esophageal Sphincter 12 71
Achalasia of Cardia 12 32
Lack of Reflex Relaxation of Lower Oesophageal Sphincter 12
Idiopathic Achalasia of Esophagus 52
Achalasia of Esophagus 12
Idiopathic Achalasia 52
Primary Achalasia 52
Achalasia Cardia 52

Classifications:



External Ids:

Disease Ontology 12 DOID:9164
ICD9CM 34 530.0
MeSH 43 D004931
NCIt 49 C84699
SNOMED-CT 67 45564002
ICD10 32 K22.0
UMLS 71 C0014848 C1321756 C2939435

Summaries for Achalasia

NIH Rare Diseases : 52 Achalasia is a disorder of the esophagus, the tube that carries food from the mouth to the stomach. It is characterized by enlargement of the esophagus, impaired ability of the esophagus to push food down toward the stomach (peristalsis), and failure of the ring-shaped muscle at the bottom of the esophagus (the lower esophageal sphincter) to relax. Achalasia is typically diagnosed in individuals between 25 and 60 years of age. The exact etiology is unknown, however, symptoms are caused by damage to the nerves of the esophagus. Familial studies have shown evidence of a potential genetic influence. When a genetic influence is suspected, achalasia is called familial esophageal achalasia. Treatment is aimed at reducing the pressure at the lower esophageal sphincter and may include Botox , medications, or surgery.

MalaCards based summary : Achalasia, also known as esophageal achalasia, is related to achalasia-addisonianism-alacrima syndrome and gastroesophageal reflux. An important gene associated with Achalasia is AAAS (Aladin WD Repeat Nucleoporin), and among its related pathways/superpathways are cAMP signaling pathway and Neuroscience. The drugs Prednisone and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include testes, smooth muscle and lung, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An esophageal disease that is characterized by an inability of the esophagus to move food toward the stomach resulting from the lower esophogeal sphincter not fully relaxing during swallowing.

Wikipedia : 74 Esophageal achalasia, often referred to simply as achalasia, is a failure of smooth muscle fibers to... more...

Related Diseases for Achalasia

Diseases related to Achalasia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 528, show less)
# Related Disease Score Top Affiliating Genes
1 achalasia-addisonianism-alacrima syndrome 34.7 TRAPPC11 MC2R GMPPA AAAS
2 gastroesophageal reflux 31.2 VIP TP53 NPY GAST
3 hirschsprung disease 1 30.6 VIP RET NPY NOS1 KIT GDNF
4 hypertrophic pyloric stenosis 30.5 RET NOS1 GAST
5 intestinal pseudo-obstruction 30.4 RET EDN3 ACHE
6 gastric leiomyoma 30.3 VIPR1 KIT
7 rare tumor 30.3 RET KIT
8 pyloric stenosis 30.2 RET NOS1 GDNF GAST BLVRB
9 small cell carcinoma 30.0 TP53 KIT GAST ENO2
10 gastric adenocarcinoma 29.8 VIPR1 VIP TP53 KIT GAST
11 hypoganglionosis 29.7 RET GDNF BLVRB ACHE
12 thymoma 29.7 TP53 PTPN22 KIT ENO2
13 central hypoventilation syndrome, congenital 29.7 RET GDNF EDN3
14 hemangioma 29.6 TP53 RET KIT ENO2
15 pelvic organ prolapse 29.6 VIP TP53 NPY
16 intestinal obstruction 29.6 RET KIT GDNF EDN3 ACHE
17 megacolon 29.6 VIP RET KIT GDNF EDN3 BLVRB
18 small cell cancer of the lung 29.4 VIP TP53 KIT GAST ENO2
19 constipation 29.3 VIP RET NPY NOS1 KIT GDNF
20 achalasia, familial esophageal 12.9
21 achalasia-microcephaly syndrome 12.7
22 moyamoya disease 6 with or without achalasia 12.7
23 alacrima, achalasia, and mental retardation syndrome 12.7
24 deafness, congenital, with vitiligo and achalasia 12.7
25 mental retardation, x-linked, syndromic 17 12.1
26 megaesophagus 11.9
27 jackhammer esophagus 11.5
28 sjogren syndrome 11.5
29 muscular dystrophy, limb-girdle, autosomal recessive 18 11.5
30 dysphagia 11.2
31 aortic aneurysm, familial abdominal, 1 11.2
32 posterior column ataxia with retinitis pigmentosa 11.2
33 gmppa-cdg 11.2
34 esophagitis 10.8
35 esophageal cancer 10.7
36 peptic esophagitis 10.6
37 dyskinesia of esophagus 10.6
38 chagas disease 10.6
39 pineal region teratoma 10.5 KIT ENO2
40 jejunal neoplasm 10.5 KIT ENO2
41 plexiform schwannoma 10.5 KIT ENO2
42 retroperitoneal hemangiopericytoma 10.5 KIT ENO2
43 atypical follicular adenoma 10.5 RET ENO2
44 gastric hemangioma 10.5 KIT ENO2
45 barrett esophagus 10.5
46 rectum neuroendocrine neoplasm 10.5 VIP GAST
47 cutaneous ganglioneuroma 10.5 KIT ENO2
48 neurogenic bowel 10.5 VIP ACHE
49 hernia, hiatus 10.5
50 cervical neuroblastoma 10.5 VIP ENO2
51 aspiration pneumonia 10.4
52 goblet cell carcinoid 10.4 GAST ENO2
53 gastric gastrinoma 10.4 GAST ENO2
54 liver leiomyosarcoma 10.4 KIT ENO2
55 glucagonoma 10.4 VIP GAST
56 medullary sponge kidney 10.4 RET GDNF
57 breast leiomyosarcoma 10.4 KIT ENO2
58 pancreatic cholera 10.4 VIP GAST
59 endocrine pancreas disease 10.4 VIP GAST
60 appendix lymphoma 10.4 GAST ENO2
61 pneumothorax 10.4
62 endobronchial leiomyoma 10.4 KIT ENO2
63 binswanger's disease 10.4 VIP ACHE
64 carcinoid tumors, intestinal 10.4 GAST ENO2
65 esophageal disease 10.4
66 colon neuroendocrine neoplasm 10.4 VIP ENO2
67 persian gulf syndrome 10.4 VIP ACHE
68 extracranial neuroblastoma 10.4 VIP ENO2
69 autonomic nervous system benign neoplasm 10.4 VIP RET ENO2
70 peripheral nervous system benign neoplasm 10.4 VIP RET ENO2
71 intratubular embryonal carcinoma 10.4 TP53 KIT
72 ganglioneuroma 10.3 VIP RET ENO2
73 bile duct mucinous adenocarcinoma 10.3 TP53 ENO2
74 leprosy 2 10.3 VIP NPY
75 squamous cell carcinoma 10.3
76 somatostatinoma 10.3 VIP GAST ENO2
77 frontal lobe neoplasm 10.3 TP53 ENO2
78 anorexia nervosa 10.3
79 small intestine benign neoplasm 10.3 KIT ENO2
80 adenocarcinoma 10.3
81 esophagitis, eosinophilic, 1 10.3
82 breast malignant phyllodes tumor 10.3 TP53 KIT
83 multiple mucosal neuroma 10.3 RET GDNF ENO2
84 leptin deficiency or dysfunction 10.3
85 familial glucocorticoid deficiency 10.3
86 neuroendocrine carcinoma 10.3 KIT GAST ENO2
87 varicose veins 10.3
88 systemic scleroderma 10.2
89 autonomic dysfunction 10.2
90 thyroid gland medullary carcinoma 10.2 RET GDNF GAST
91 conventional fibrosarcoma 10.2 TP53 KIT ENO2
92 mature teratoma 10.2 TP53 KIT ENO2
93 esophageal varix 10.2
94 mixed cell type cancer 10.2 TP53 KIT ENO2
95 cystic teratoma 10.2 TP53 KIT ENO2
96 connective tissue benign neoplasm 10.2 TP53 KIT ENO2
97 thyroid carcinoma, familial medullary 10.2 RET GDNF GAST
98 embryonal sarcoma 10.2 TP53 KIT
99 thymic carcinoma 10.2 TP53 KIT ENO2
100 fibrous histiocytoma 10.2 TP53 KIT ENO2
101 skeletal muscle cancer 10.2 TP53 KIT ENO2
102 carcinoid syndrome 10.2 NPY ENO2
103 muscle cancer 10.2 TP53 KIT ENO2
104 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.2
105 spinal cord oligodendroglioma 10.2 TP53 ENO2
106 endometrial small cell carcinoma 10.2 VIP KIT GAST ENO2
107 paraganglioma 10.2 RET KIT ENO2
108 central nervous system benign neoplasm 10.2 TP53 RET ENO2
109 merkel cell carcinoma 10.2 TP53 KIT ENO2
110 autoimmune disease 10.2
111 premature ovarian failure 7 10.2
112 respiratory failure 10.2
113 pneumonia 10.2
114 eating disorder 10.2
115 neuropathy 10.2
116 47,xyy 10.2
117 inflammatory myofibroblastic tumor 10.2 TP53 KIT ENO2
118 cardiovascular organ benign neoplasm 10.2 TP53 RET ENO2
119 dermatofibrosarcoma protuberans 10.2 TP53 KIT ENO2
120 prostate neuroendocrine neoplasm 10.2 TP53 ENO2
121 islet cell tumor 10.2 VIP RET GAST ENO2
122 goldberg-shprintzen syndrome 10.2 RET GDNF EDN3
123 neuroendocrine tumor 10.2 VIP RET GAST ENO2
124 autosomal recessive disease 10.2
125 autonomic neuropathy 10.2
126 swallowing disorders 10.2
127 glomangiomatosis 10.2 TP53 KIT
128 endocrine organ benign neoplasm 10.2 TP53 RET ENO2
129 waardenburg's syndrome 10.2 RET KIT EDN3
130 neuroma 10.1 RET KIT GDNF ENO2
131 leiomyosarcoma 10.1 TP53 KIT ENO2
132 down syndrome 10.1
133 microcephaly 10.1
134 gastroparesis 10.1
135 mediastinitis 10.1
136 chickenpox 10.1
137 in situ carcinoma 10.1
138 mycobacterium fortuitum 10.1
139 specific language disorder 10.1
140 seminoma 10.1 TP53 KIT ENO2
141 cerebrovascular benign neoplasm 10.1 TP53 ENO2
142 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.1
143 candidiasis 10.1
144 benign mesothelioma 10.1
145 normal pressure hydrocephalus 10.1 VIP NPY GDNF
146 adrenal cortex disease 10.1 TP53 PTPN22 MC2R
147 cerebellum cancer 10.1 TP53 ENO2
148 status epilepticus 10.1 NPY ENO2 ACHE
149 scleroderma, familial progressive 10.1
150 tracheoesophageal fistula with or without esophageal atresia 10.1
151 enterocolitis 10.1
152 asthma 10.1
153 tracheomalacia 10.1
154 lung abscess 10.1
155 leiomyoma 10.1
156 guillain-barre syndrome 10.1
157 hypothyroidism 10.1
158 duodenal ulcer 10.1
159 gastritis 10.1
160 myopathy 10.1
161 leiomyomatosis 10.1
162 intravenous leiomyomatosis 10.1
163 herpes simplex 10.1
164 amyloidosis 10.1
165 hypereosinophilic syndrome 10.1
166 48,xyyy 10.1
167 overgrowth syndrome 10.1
168 cerebellar medulloblastoma 10.0 TP53 ENO2
169 intussusception 10.0
170 sarcoidosis 1 10.0
171 myasthenia gravis 10.0
172 body mass index quantitative trait locus 11 10.0
173 ataxia and polyneuropathy, adult-onset 10.0
174 body mass index quantitative trait locus 9 10.0
175 body mass index quantitative trait locus 8 10.0
176 body mass index quantitative trait locus 4 10.0
177 bulimia nervosa 10.0
178 body mass index quantitative trait locus 10 10.0
179 body mass index quantitative trait locus 7 10.0
180 body mass index quantitative trait locus 12 10.0
181 body mass index quantitative trait locus 14 10.0
182 body mass index quantitative trait locus 18 10.0
183 body mass index quantitative trait locus 19 10.0
184 body mass index quantitative trait locus 20 10.0
185 esophageal atresia 10.0
186 gastric ulcer 10.0
187 keratoconjunctivitis sicca 10.0
188 esophageal candidiasis 10.0
189 multiple endocrine neoplasia 10.0
190 pleural empyema 10.0
191 liver cirrhosis 10.0
192 dystonia 10.0
193 congestive heart failure 10.0
194 bronchitis 10.0
195 peptic ulcer disease 10.0
196 lung disease 10.0
197 muscular dystrophy 10.0
198 myotonic dystrophy 10.0
199 dysautonomia 10.0
200 isolated tracheoesophageal fistula 10.0
201 pik3ca-related overgrowth syndrome 10.0
202 syringomyelia, noncommunicating isolated 10.0
203 triiodothyronine receptor auxiliary protein 10.0
204 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.0
205 deficiency anemia 10.0
206 epilepsy 10.0
207 syringomyelia 10.0
208 uremia 10.0
209 diabetes mellitus 10.0
210 central nervous system primitive neuroectodermal neoplasm 10.0 TP53 ENO2
211 cystitis 10.0 TP53 KIT GDNF
212 cardiac arrhythmia 9.9
213 stroke, ischemic 9.9
214 cyanosis, transient neonatal 9.9
215 leukemia, acute lymphoblastic 3 9.9
216 foodborne botulism 9.9
217 atrioventricular block 9.9
218 cardiac arrest 9.9
219 dumping syndrome 9.9
220 gastroenteritis 9.9
221 sensory peripheral neuropathy 9.9
222 papilloma 9.9
223 bronchiolitis 9.9
224 eosinophilic gastroenteritis 9.9
225 muscular atrophy 9.9
226 gastrointestinal system disease 9.9
227 ileus 9.9
228 measles 9.9
229 neurofibromatosis 9.9
230 keratoconjunctivitis 9.9
231 bronchiectasis 9.9
232 hypoglycemia 9.9
233 syncope 9.9
234 migraine with or without aura 1 9.9 VIPR1 VIP NPY NOS1
235 ganglioneuroblastoma 9.9 VIP TP53 NPY ENO2
236 glucocorticoid deficiency 1 9.9 NPY MC2R
237 alcohol dependence 9.9
238 amyotrophic lateral sclerosis 1 9.9
239 atrial standstill 1 9.9
240 breast cancer 9.9
241 hepatocellular carcinoma 9.9
242 visceral myopathy 9.9
243 mesothelioma, malignant 9.9
244 volvulus of midgut 9.9
245 williams-beuren syndrome 9.9
246 autism 9.9
247 neuropathy, hereditary sensory and autonomic, type iii 9.9
248 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.9
249 moyamoya disease 1 9.9
250 thymoma, familial 9.9
251 kearns-sayre syndrome 9.9
252 branchiootic syndrome 1 9.9
253 body mass index quantitative trait locus 1 9.9
254 gastrointestinal stromal tumor 9.9
255 gastric cancer 9.9
256 muscle hypertrophy 9.9
257 sleep apnea 9.9
258 lymphoma 9.9
259 ptosis 9.9
260 cholelithiasis 9.9
261 dermatomyositis 9.9
262 portal hypertension 9.9
263 sarcoma 9.9
264 heart disease 9.9
265 allergic hypersensitivity disease 9.9
266 polyneuropathy 9.9
267 gonadal dysgenesis 9.9
268 pericarditis 9.9
269 ectodermal dysplasia 9.9
270 lateral sclerosis 9.9
271 wernicke encephalopathy 9.9
272 aspiration pneumonitis 9.9
273 lipid pneumonia 9.9
274 turner syndrome 9.9
275 signet ring cell adenocarcinoma 9.9
276 mastocytosis 9.9
277 plexopathy 9.9
278 spindle cell sarcoma 9.9
279 neuromuscular disease 9.9
280 gastroesophageal junction adenocarcinoma 9.9
281 poliomyelitis 9.9
282 thyroid gland disease 9.9
283 peripheral nervous system disease 9.9
284 connective tissue disease 9.9
285 hyperthyroidism 9.9
286 peritonitis 9.9
287 actinomycosis 9.9
288 pulmonary embolism 9.9
289 boerhaave syndrome 9.9
290 chromosomal triplication 9.9
291 cryptogenic cirrhosis 9.9
292 encephalopathy 9.9
293 hypotonia 9.9
294 myotonia 9.9
295 virus-associated trichodysplasia spinulosa 9.9
296 primary adrenal insufficiency 9.9
297 multiple endocrine neoplasia, type i 9.7 VIP RET GAST
298 ewing sarcoma 9.7 TP53 RET NPY KIT ENO2
299 acanthosis nigricans 9.7
300 diabetes insipidus, neurohypophyseal 9.7
301 gilbert syndrome 9.7
302 renal cell carcinoma, nonpapillary 9.7
303 hypertelorism 9.7
304 laryngomalacia 9.7
305 lipomatosis, multiple 9.7
306 systemic lupus erythematosus 9.7
307 treacher collins syndrome 1 9.7
308 mastocytosis, cutaneous 9.7
309 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 1 9.7
310 myositis 9.7
311 multiple endocrine neoplasia, type iib 9.7
312 juvenile polyposis syndrome 9.7
313 hutchinson-gilford progeria syndrome 9.7
314 pyloric stenosis, infantile hypertrophic, 1 9.7
315 rheumatoid arthritis 9.7
316 thrombophilia due to thrombin defect 9.7
317 tuberous sclerosis 1 9.7
318 vitiligo-associated multiple autoimmune disease susceptibility 6 9.7
319 anemia, autoimmune hemolytic 9.7
320 anemia, hypochromic microcytic, with iron overload 1 9.7
321 chiari malformation type ii 9.7
322 ascites, chylous 9.7
323 lung cancer 9.7
324 dubowitz syndrome 9.7
325 duodenal atresia 9.7
326 hypoadrenocorticism, familial 9.7
327 ocular motor apraxia 9.7
328 3-methylglutaconic aciduria, type iii 9.7
329 pancreatic cancer 9.7
330 pancreatic agenesis 1 9.7
331 pituitary hormone deficiency, combined, 2 9.7
332 reticulum cell sarcoma 9.7
333 sandhoff disease 9.7
334 smith-lemli-opitz syndrome 9.7
335 insulin-like growth factor i 9.7
336 asplenia, isolated congenital 9.7
337 tay-sachs disease 9.7
338 graves disease 1 9.7
339 opitz gbbb syndrome, type i 9.7
340 adrenoleukodystrophy 9.7
341 sarcoma, synovial 9.7
342 fabry disease 9.7
343 leiomyomatosis, diffuse, with alport syndrome 9.7
344 helicobacter pylori infection 9.7
345 gallbladder disease 1 9.7
346 budd-chiari syndrome 9.7
347 supranuclear palsy, progressive, 1 9.7
348 leukemia, acute myeloid 9.7
349 orthostatic intolerance 9.7
350 vitiligo-associated multiple autoimmune disease susceptibility 1 9.7
351 aortic aneurysm, familial thoracic 1 9.7
352 hypereosinophilic syndrome, idiopathic 9.7
353 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 2 9.7
354 human immunodeficiency virus type 1 9.7
355 hepatitis c virus 9.7
356 visceral neuropathy, familial, autosomal dominant 9.7
357 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 4 9.7
358 malaria 9.7
359 breast-ovarian cancer, familial 2 9.7
360 lung cancer susceptibility 3 9.7
361 mental retardation with language impairment and with or without autistic features 9.7
362 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 9.7
363 cholangiocarcinoma 9.7
364 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.7
365 chorea, childhood-onset, with psychomotor retardation 9.7
366 mirage syndrome 9.7
367 cryptogenic organizing pneumonia 9.7
368 paralytic poliomyelitis 9.7
369 inflammatory bowel disease 9.7
370 hypochromic microcytic anemia 9.7
371 rheumatic heart disease 9.7
372 oppositional defiant disorder 9.7
373 autism spectrum disorder 9.7
374 aphasia 9.7
375 crest syndrome 9.7
376 atrial fibrillation 9.7
377 scoliosis 9.7
378 cold-induced sweating syndrome 9.7
379 myelomeningocele 9.7
380 hepatoid adenocarcinoma 9.7
381 thrombosis 9.7
382 myoglobinuria 9.7
383 adenoid cystic carcinoma 9.7
384 sensorineural hearing loss 9.7
385 xerophthalmia 9.7
386 pleomorphic lipoma 9.7
387 mumps 9.7
388 gastric lymphoma 9.7
389 pre-eclampsia 9.7
390 esophagus sarcoma 9.7
391 anhidrosis 9.7
392 pertussis 9.7
393 hypoparathyroidism 9.7
394 tetanus 9.7
395 hemopericardium 9.7
396 cardiac tamponade 9.7
397 mitral valve insufficiency 9.7
398 pericardial effusion 9.7
399 hypertrophic cardiomyopathy 9.7
400 neurogenic bladder 9.7
401 goiter 9.7
402 primary biliary cirrhosis 9.7
403 bronchopneumonia 9.7
404 chronic progressive external ophthalmoplegia 9.7
405 pseudobulbar palsy 9.7
406 telangiectasis 9.7
407 choreatic disease 9.7
408 uveitis 9.7
409 acute cystitis 9.7
410 pulmonary sarcoidosis 9.7
411 tuberous sclerosis 9.7
412 kwashiorkor 9.7
413 beriberi 9.7
414 squamous cell papilloma 9.7
415 acquired gastric outlet stenosis 9.7
416 toxic shock syndrome 9.7
417 lymphangioma 9.7
418 urticaria 9.7
419 angioedema 9.7
420 diffuse scleroderma 9.7
421 renovascular hypertension 9.7
422 mental depression 9.7
423 hypoglycemic coma 9.7
424 mitral valve stenosis 9.7
425 peritoneal mesothelioma 9.7
426 neuritis 9.7
427 impotence 9.7
428 dysostosis 9.7
429 cholecystitis 9.7
430 myeloproliferative neoplasm 9.7
431 hepatitis 9.7
432 keratopathy 9.7
433 motor neuron disease 9.7
434 pancreas disease 9.7
435 transitional cell carcinoma 9.7
436 hemangioma of liver 9.7
437 bronchiolitis obliterans 9.7
438 acute pancreatitis 9.7
439 cystadenocarcinoma 9.7
440 rhabdomyosarcoma 9.7
441 ischemia 9.7
442 chronic granulomatous disease 9.7
443 central nervous system disease 9.7
444 gm2 gangliosidosis 9.7
445 brain stem infarction 9.7
446 choriocarcinoma 9.7
447 mucinous cystadenocarcinoma 9.7
448 aortic aneurysm 9.7
449 verrucous carcinoma 9.7
450 pulmonary fibrosis 9.7
451 duodenogastric reflux 9.7
452 liver disease 9.7
453 biliary dyskinesia 9.7
454 carcinosarcoma 9.7
455 esophagus adenocarcinoma 9.7
456 intrahepatic cholangiocarcinoma 9.7
457 tubular adenocarcinoma 9.7
458 neurotic disorder 9.7
459 blepharospasm 9.7
460 sleep disorder 9.7
461 hemolytic anemia 9.7
462 conjunctivitis 9.7
463 inherited metabolic disorder 9.7
464 mitochondrial myopathy 9.7
465 b-cell lymphoma 9.7
466 malignant pleural mesothelioma 9.7
467 situs inversus 9.7
468 end stage renal disease 9.7
469 barrett's adenocarcinoma 9.7
470 arthritis 9.7
471 hodgkin's lymphoma, lymphocytic-histiocytic predominance 9.7
472 malignant hyperthermia 9.7
473 nervous system disease 9.7
474 vasculitis 9.7
475 myeloid leukemia 9.7
476 crohn's disease 9.7
477 rubella 9.7
478 lupus erythematosus 9.7
479 status asthmaticus 9.7
480 croup 9.7
481 diabetes insipidus 9.7
482 cholangitis 9.7
483 encephalitis 9.7
484 fasciitis 9.7
485 neurofibroma 9.7
486 irritable bowel syndrome 9.7
487 miliary tuberculosis 9.7
488 limb-girdle muscular dystrophy 9.7
489 berardinelli-seip congenital lipodystrophy 9.7
490 congenital disorders of n-linked glycosylation and multiple pathway 9.7
491 acquired hemophilia 9.7
492 adrenomyeloneuropathy 9.7
493 amyloidosis aa 9.7
494 autoimmune gastrointestinal dysmotility 9.7
495 broken heart syndrome 9.7
496 bronchogenic cyst 9.7
497 chiari malformation 9.7
498 chromosome 1p duplication 9.7
499 dextrocardia with situs inversus 9.7
500 gangliosidosis 9.7
501 homologous wasting disease 9.7
502 laryngeal papillomatosis 9.7
503 lymphosarcoma 9.7
504 mallory-weiss syndrome 9.7
505 mycobacterium abscessus 9.7
506 osteochondroma 9.7
507 primary orthostatic hypotension 9.7
508 pure autonomic failure 9.7
509 raynaud phenomenon 9.7
510 depression 9.7
511 back pain 9.7
512 cerebral atrophy 9.7
513 headache 9.7
514 spasticity 9.7
515 tremor 9.7
516 rare neurodegenerative disease 9.7
517 rare lymphatic malformation 9.7
518 acute pandysautonomia 9.7
519 mucinous cystadenocarcinoma of the pancreas 9.7
520 prepubertal anorexia nervosa 9.7
521 heavy chain deposition disease 9.7
522 right aortic arch 9.7
523 polyendocrinopathy 9.7
524 hydrocephalus 9.6 VIP TP53 NPY GDNF ENO2
525 thyroid gland cancer 9.6 TP53 RET KIT GDNF GAST ENO2
526 huntington disease 9.6 TP53 NPY NOS1 GDNF ACHE
527 pheochromocytoma 9.4 VIP RET NPY KIT GDNF ENO2
528 neuroblastoma 9.2 VIP TP53 RET NPY KIT GDNF

Graphical network of the top 20 diseases related to Achalasia:



Diseases related to Achalasia

Symptoms & Phenotypes for Achalasia

GenomeRNAi Phenotypes related to Achalasia according to GeneCards Suite gene sharing:

26 (showing 9, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.68 KIT RET
2 Decreased viability GR00221-A-2 9.68 RET
3 Decreased viability GR00221-A-4 9.68 RET
4 Decreased viability GR00240-S-1 9.68 TP53 VIPR1
5 Decreased viability GR00249-S 9.68 EDN3 GMPPA GUCY1A1 MC2R NOS1 TP53
6 Decreased viability GR00301-A 9.68 KIT RET
7 Decreased viability GR00381-A-1 9.68 GUCY1A1
8 Decreased viability GR00386-A-1 9.68 AAAS GUCY1A1
9 Decreased viability GR00402-S-2 9.68 ENO2 GMPPA MC2R NPY RET TP53

MGI Mouse Phenotypes related to Achalasia:

45 (showing 11, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.31 AAAS ACHE EDN3 ENO2 GDNF KIT
2 homeostasis/metabolism MP:0005376 10.24 AAAS ACHE BLVRB FLVCR1 GAST GUCY1A1
3 cardiovascular system MP:0005385 10.22 FLVCR1 GDNF GUCY1A1 KIT MC2R NOS1
4 growth/size/body region MP:0005378 10.22 AAAS ACHE ENO2 FLVCR1 GDNF KIT
5 digestive/alimentary MP:0005381 10.2 AAAS EDN3 GAST GDNF KIT NOS1
6 endocrine/exocrine gland MP:0005379 10.17 AAAS GAST GDNF KIT MC2R NOS1
7 mortality/aging MP:0010768 10.17 ACHE EDN3 FLVCR1 GAST GDNF GUCY1A1
8 nervous system MP:0003631 10.03 AAAS ACHE EDN3 ENO2 GDNF GUCY1A1
9 renal/urinary system MP:0005367 9.76 FLVCR1 GDNF KIT NOS1 NPY PTPN22
10 reproductive system MP:0005389 9.61 AAAS ACHE FLVCR1 GDNF KIT NOS1
11 respiratory system MP:0005388 9.32 ACHE ENO2 FLVCR1 GUCY1A1 KIT NOS1

Drugs & Therapeutics for Achalasia

Drugs for Achalasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 86, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
3
Remifentanil Approved Phase 4 132875-61-7 60815
4
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
5 Hormones Phase 4
6 Antineoplastic Agents, Hormonal Phase 4
7 Hormone Antagonists Phase 4
8 glucocorticoids Phase 4
9 Anti-Inflammatory Agents Phase 4
10 Anesthetics, General Phase 4
11 Analgesics Phase 4
12 Anesthetics, Intravenous Phase 4
13
Ceftazidime Approved Phase 2, Phase 3 72558-82-8, 78439-06-2 5481173
14 Tin Fluorides Phase 3
15 Anti-Bacterial Agents Phase 3
16 Anti-Infective Agents Phase 3
17 Antibiotics, Antitubercular Phase 3
18
Nitric Oxide Approved Phase 1, Phase 2 10102-43-9 145068
19
Alendronate Approved Phase 2 66376-36-1, 121268-17-5 2088
20
Naloxegol Approved Phase 2 854601-70-0
21
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 5280795 6221
22 Cola Phase 2
23 Micronutrients Phase 2
24 Trace Elements Phase 2
25 Vitamins Phase 2
26 Nutrients Phase 2
27 Diphosphonates Phase 2
28 Calcium, Dietary Phase 2
29 Calciferol Phase 2
30 Narcotics Phase 2
31 Analgesics, Opioid Phase 2
32 Narcotic Antagonists Phase 2
33
Calcium Nutraceutical Phase 2 7440-70-2 271
34
Mirabegron Approved Early Phase 1 223673-61-8 9865528
35
Methylene blue Approved, Investigational 61-73-4
36
Clavulanate Approved, Vet_approved 58001-44-8 5280980
37
Amoxicillin Approved, Vet_approved 26787-78-0 33613
38
Cefazolin Approved 25953-19-9 656510 33255
39
tannic acid Approved 1401-55-4
40
Benzocaine Approved, Investigational 94-09-7, 1994-09-7 2337
41
Histamine Approved, Investigational 51-45-6 774
42
Promethazine Approved, Investigational 60-87-7 4927
43
Ondansetron Approved 99614-02-5 4595
44
Diphenhydramine Approved, Investigational 58-73-1, 147-24-0 3100
45 Orange Approved
46
Budesonide Approved 51333-22-3 63006 5281004
47
Formaldehyde Approved, Vet_approved 50-00-0 712
48
Ropivacaine Approved 84057-95-4 71273 175805
49
Acetylcholine Approved, Investigational 51-84-3 187
50
Esomeprazole Approved, Investigational 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
51
Dopamine Approved 51-61-6, 62-31-7 681
52
Domperidone Approved, Investigational, Vet_approved 57808-66-9 3151
53 Lugol's solution
54 Cephalosporins
55 Adrenergic beta-Agonists Early Phase 1
56 Adrenergic Agents Early Phase 1
57 Adrenergic Agonists Early Phase 1
58 Adrenergic beta-3 Receptor Agonists Early Phase 1
59 Hypnotics and Sedatives
60 Ulipristal acetate 126784-99-4
61 Anti-Allergic Agents
62 Anti-Anxiety Agents
63 Histamine Antagonists
64 Emetics
65
Histamine Phosphate 51-74-1 65513
66 Psychotropic Drugs
67 Dermatologic Agents
68 Histamine H1 Antagonists
69 Antipsychotic Agents
70 Technetium Tc 99m Sulfur Colloid
71 Anesthetics, Local
72 Liver Extracts
73 Gentamicins
74 abobotulinumtoxinA
75 Neurotransmitter Agents
76 Cholinergic Agents
77 Botulinum Toxins
78 Botulinum Toxins, Type A
79 Hemostatics
80 Dopamine Agents
81 Dopamine Antagonists
82 Antacids
83 Anti-Ulcer Agents
84 Antiemetics
85 Gastrointestinal Agents
86
Serotonin Investigational, Nutraceutical 50-67-9 5202

Interventional clinical trials:

(showing 122, show less)
# Name Status NCT ID Phase Drugs
1 Personalized Peroral Endoscopic Myotomy for Achalasia Unknown status NCT01570621 Phase 4
2 A Pilot Study Assessing the Efficacy of Steroids in the Treatment of Achalasia Enrolling by invitation NCT01903486 Phase 4 Apo-Prednisone Cordorol, Detasone - Prednisone
3 Prospective Single-Blinded Randomized Controlled Trial Comparing Botox or Botox With Esophageal Dilation in Patients With Achalasia Enrolling by invitation NCT03654066 Phase 4 Botulinum toxin type A
4 Botulinum Toxin Pyloroplasty to Reduce Postoperative Nausea and Vomiting After Sleeve Gastrectomy Enrolling by invitation NCT03701919 Phase 4 Botulinum toxin pyloroplasty;Normal saline pyloric injection
5 Influence of Intraoperative Opioids (Oxycodone/Fentanyl) Usage on the Post-operative Pain Management of Peroral Endoscopic Myotomy (POEM) Not yet recruiting NCT04177342 Phase 4 Fentanyl;Oxycodone
6 Comparison of Solid-State Esophageal Manometry and Water Perfused Anorectal Manometry Catheters With Air Filled Multi-Balloon Esophageal and Anorectal Manometry Catheters Terminated NCT00204763 Phase 4
7 Single- Versus Multiple-dose Antimicrobial Prophylaxis for The Prevention of Infectious Complications Associated With Peroral Endoscopic Myotomy(POEM) for Achalasia: A Triple-Blind, Randomized Controlled, Non-Inferiority Trial Unknown status NCT03404739 Phase 2, Phase 3 Saline Solution;Ceftazidime
8 Peroral Endoscopic Myotomy for Primary Esophageal Achalasia Completed NCT01560559 Phase 3
9 Randomized Control Study Comparing Single-Versus Multiple-dose Antimicrobial Prophylaxis for Peroral Endoscopic Myotomy in Achalasia Recruiting NCT03784365 Phase 3 One dose of Cefo-perazone Sulbactum
10 Prospective Study on the Feasibility and Effectiveness of Per-Oral Endoscopic Myotomy (P.O.E.M.) for Treatment of Primary Esophageal Motility Disorders Unknown status NCT01524458 Phase 1, Phase 2
11 Per-Oral Endoscopic Myotomy (P.O.E.M.) for Treatment of Primary Esophageal Motility Disorders Unknown status NCT01524471 Phase 2
12 Efficacy of Dark Chocolate in Achalasia Patients: Placebo-Controlled Study Unknown status NCT00790465 Phase 1, Phase 2
13 Endoscopic Submucosal Tunnel Dissection for Endolumenal Partial Myotomy of the Lower Esophageal Sphincter for Achalasia Unknown status NCT01302288 Phase 2
14 Endoscopic Submucosal Tunnel Dissection for Endolumenal Partial Myotomy of the Lower Esophageal Sphincter for Atypical Primary Motility Disorders Such as Achalasia and Esophageal Spasm Unknown status NCT01302301 Phase 2
15 Prospective Study on the Feasibility and Results of the Treatment of Idiopathic Achalasia With the POEM (Per Oral Endoscopic Myotomy) Technique Completed NCT02259283 Phase 2
16 Peroral Endoscopic Myotomy (POEM) for the Treatment of Achalasia Completed NCT02073578 Phase 1, Phase 2
17 Randomized Study to Compare Pneumatic Dilatation With Surgical Myotomy for Treatment of Achalasia - Long Term Follow up Completed NCT02086669 Phase 2
18 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-dose, Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 in Patients With Achalasia Completed NCT02931565 Phase 2 IW-1701;Matching Placebo
19 Endoscopic Esophageal Myotomy for the Treatment of Achalasia Completed NCT01873300 Phase 1, Phase 2
20 Endoscopic Injection of Botulinum Toxin in Patients With Hypercontractile Esophageal Motility Disorders: a Prospective, Randomized, Double-blind, Controlled Study Completed NCT01955174 Phase 2 Esophageal endoscopic injection of botulinum toxin
21 The Impact of Bisphosphonates on Bone Loss in Patients Undergoing Surgery and Postoperative Chemotherapy for Gynecologic Malignancies. Completed NCT00593580 Phase 2 placebo;alendronate/cholecalciferol
22 Movantik for Opioid-Related Esophageal Disorders Terminated NCT02998606 Phase 2 Naloxegol;Placebo Oral Capsule
23 Phase II Study of Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD Withdrawn NCT01025739 Phase 2
24 Clinical Impact of Peroral Endoscopic Myotomy for Esophageal Achalasia Unknown status NCT01649843
25 A Prospective Trial Comparing POEM to Pneumatic Dilatation for Treatment of Achalasia Cardia Unknown status NCT02025790
26 Screening for Dysplasia in Longstanding Idiopathic Achalasia: a Prospective Study Unknown status NCT02010983
27 Peroral Endoscopic Myotomy for Esophageal Achalasia: Randomized Comparison of Water-Jet Assisted Versus Conventional Dissection Technique Unknown status NCT01742494
28 Peroral Endoscopic Remyotomy for Failed Heller Myotomy Unknown status NCT01637311
29 POEM a Novel Endoscopic Treatment for Achalasia Unknown status NCT01512719
30 Short and Long Term Outcomes of Heller Myotomy Unknown status NCT00519220
31 Peroral Endoscopic Myotomy Versus Pneumatic Dilation for Esophageal Achalasia: a Prospective Randomized Controlled Trial Unknown status NCT01768091
32 Safety,Efficacy and Cost-effectiveness of Snare-assisted POEM for Treatment of Esophageal Achalasia Unknown status NCT02999451
33 Bacteremia and Procalcitonin Levels in Peroral Endoscopic Myotomy for Achalasia Unknown status NCT01750385 no antibiotic prophylaxis;second-generation cephalosporin
34 Laparoscopy Heller Myotomy With Fundoplication Associated Versus Peroral Endoscopic Myotomy (POEM) Unknown status NCT02138643
35 To Assess the Feasibility of Same Day Discharge Following a POEM Procedure Unknown status NCT02572193
36 Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study Unknown status NCT03411252 Early Phase 1 Mirabegron 50 MG;Placebo
37 Efficacy and Safety Study of Hot Water Drinking Therapy in Achalasia Patients Unknown status NCT01863966
38 Endoscopic Submucosal Tunnel Dissection for Endoluminal Partial Myotomy of the Lower Esophageal Sphincter in Patients With Spastic Esophageal Disorders Such as Achalasia Unknown status NCT02425033
39 A Randomized Comparison of Laparoscopic Myotomy and Pneumatic Dilatation for Achalasia Unknown status NCT00188344
40 Clinical Outcomes of Peroral Endoscopic Myotomy for Esophageal Outflow Obstruction Unknown status NCT02989883
41 Achalasia; Mechanisms Underlying Persistent Symptoms After Treatment Unknown status NCT02055469
42 Peroral Endoscopic Myotomy (POEM) For The Treatment Of Achalasia: A Retrospective And Prospective Multicenter Registry. Unknown status NCT02162589
43 Endoscopic Submucosal Tunnel Dissection Versus Video-assisted Thoracoscopic Surgery for Upper Gastrointestinal Submucosal Tumors: a Prospective Randomized Controlled Trial Unknown status NCT01768104
44 Assessment of Esophageal Motility With Transnasal Endoscopy Unknown status NCT01658865
45 Pyloric Sphincter Pressure and Geometry Assessment Using EndoFlip Unknown status NCT02446119
46 Transnasal Endoscopic Evaluation of Swallowing: Functional Esophagoscopy Using an Ultrathin Video Endoscope in Neurogenic Dysphagia Unknown status NCT01995929
47 Observational Field Study of Acute Esophageal Food Bolus Impaction by Mean Esophageal Manometry and 24h-pH-monitoring Unknown status NCT01447823
48 Reversibility of Esophageal Dysmotilities Associated With Gastric Banding After Conversion to Gastric Bypass Unknown status NCT00680030
49 Comparison of Short Versus Long Oesophageal Myotomy in Cases With Idiopathic Achalasia: A Randomized Single Blinded Trial Completed NCT03186248
50 Randomized Prospective Trial of Laparoscopic Heller Myotomy and Partial Fundoplication for the Treatment of Idiopathic Esophageal Achalasia Completed NCT00490750
51 To Find Out the Genetic Relationship Between the Early-Onset Achalasia and AAAS Gene Completed NCT00856921
52 Observational Study of the Per-Oral Endoscopic Myotomy (POEM) Procedure Completed NCT01402518
53 Gastroesophageal Reflux in Patients With Achalasia Completed NCT00519441
54 Randomized Study of Botulinum Toxin Type A for Achalasia Completed NCT00004416 botulinum toxin type A
55 Evaluation of a Novel Endoscopic Treatment for Achalasia: Per-oral Endoscopic Esophagomyotomy (POEM) Completed NCT01770249
56 Prospective Study on the Feasibility and Effectiveness of Per-Oral Endoscopic Myotomy (P.O.E.M.) for Treatment of Primary Esophageal Motility Disorders Completed NCT01525732
57 Peroral Endoscopic Myotomy (POEM) for Treatment of Achalasia Completed NCT01584635
58 Endoscopic Submucosal Tunnel Dissection for Endoluminal Partial Myotomy of the Lower Esophageal Sphincter for Achalasia Completed NCT01399476
59 Peroral Endoscopic Myotomy (POEM) for Esophageal Motility in Patients With a Clinical Diagnosis of Achalasia Completed NCT02314741
60 Prospective Evaluation of a New Approach to Perform an Esophageal Myotomy: the Transesophageal Submucosa Approach Completed NCT02773589
61 A Prospective Randomized Trial Comparing Two Reconstructive Operation Techniques After Myotomy of Achalasia. Comparing Toupet Versus DOR. Completed NCT01933373
62 Impact of Antibiotic Prophylaxis and Conditioning Modalities in Per Oral Endoscopic Myotomy for Esophageal Motor Disorders Completed NCT03944863 Antibiotics
63 Comparison of Outcome and Complications of Anterior Versus Posterior Myotomy in Per-oral Endoscopic Myotomy (POEM) Endoscopic Procedure for Treatment of Achalasia: Randomized Single Blinded Clinical Trial Completed NCT02454335
64 Endoscopic Peroral Myotomy for Treatment of Achalasia: Pilot Study Completed NCT01405469
65 Risk of Microbial Translocation in Patients Undergoing Per-Oral Endoscopic Myotomy (POEM) for Achalasia: Antibiotic Prophylaxis or Short-therapy Completed NCT03587337
66 Ano-rectal 3D High Resolution Manometry: Normal Values and Comparison With Ultrasound Examination in Healthy Volunteers, Patients With Fecal Incontinence and Patients With Constipation Completed NCT01710579
67 A Prospective, Single Center, Proof of Concept Pilot Study of the Efficacy and Safety of Submucosal Endoscopic Myotomy With Mucosal Flap (SEMF) Technique in the Treatment of Patients With Achalasia Completed NCT01438398
68 A Clinical Study of Per Oral Endoscopic Myotomy (POEM) in Patients Suffering From Achalasia. Completed NCT01692106
69 Quality of Life After Surgery for End-stage Achalasia: Pull-down Heller-Dor vs Esophagectomy Completed NCT04152902
70 Efficacy of Anterior Versus Posterior Myotomy Approach in Per Oral Endoscopic Myotomy (POEM) for the Treatment of Achalasia - A Single Operator Analysis Completed NCT03228758
71 Per-Oral Endoscopic Esophagomyotomy (POEM) Completed NCT01635374
72 Evaluation of the Effectiveness of the SX ELLA Esophageal Degradable BD (BD Stent) Stent System Completed NCT01337206
73 Per Oral Endoscopic Myotomy (POEM) for Esophagogastric Junction Outflow Obstruction (EGOO) Completed NCT01942018
74 Prevalence and Clinical Characteristics of Patients With Jackhammer Esophagus and Symptoms of Gastroesophageal Reflux Disease Completed NCT03347903
75 Median Nerve Acustimulation Plus Medical Anti-emetic Therapy for Control Post-operative Nausea in Patients Undergoing Foregut Surgery: A Randomized Control Trial Completed NCT01510379 IV ondansetron 4 mg q 6 hours for a total of 4 doses;IV promethazine 25 mg q 6 hours prn;Elixir promethazine 25 mg q 6 hours prn after discharge
76 Safety and Efficacy of Gastric Per Oral Endoscopic Myotomy (G-POEM) in Patients With Refractory Gastroparesis Completed NCT03126513
77 The Biologic Basis of Hernia Formation Completed NCT01099033
78 Does Cricoid Pressure Reduce the Risk of Aspiration? Completed NCT02058004
79 Quality of Life Among Patients With Chronic Esophageal Disorders : Spanish Translation and Validation of the Survey "Northwestern Esophageal Quality of Life Scale" in Hispanics Completed NCT02959424
80 SmartPill Monitoring for Assessment of GI Function in SCI Completed NCT00856648
81 Comparison of Esophageal Clearance Times of Oral Budesonide Preparations Completed NCT02125851
82 What is the Physiologic and Clinical Relevance of Oesophagogastric Junction Distensibility? Studies Using Endo-Flip and 96 Hour Wireless pH System Completed NCT00481949
83 A Prospective Randomized Multi-center Study Comparing Endoscopic Pneumodilation and Per Oral Endoscopic Myotomy (POEM) as Treatment of Idiopathic Achalasia Recruiting NCT01793922
84 Incidence and Risk Factors for Development of Epidermoid Carcinoma in Esophageal Achalasia Recruiting NCT03546998
85 Functional Assessment Following Minimally Invasive Surgery of the Gastro-Esophageal Junction Recruiting NCT01799967
86 Per Oral Endoscopic Myotomy (POEM) and Prolonged Dilatation (PRD) as Additional Endoscopic Treatment Options for Achalasia and Other Esophageal Motility Disorders Recruiting NCT02518542
87 Different Surgical Procedures of Peroral Endoscopic Myotomy(POEM) for Esophageal Achalasia: a Multicenter Prospective Randomized Controlled Trial Recruiting NCT03012854
88 Development of Endoscopic Treatment for Achalasia, POEM (Per Oral Esophageal Myotomy): A Randomized Controlled Trial Recruiting NCT04180241
89 Achalasia Patient Reported Outcomes Recruiting NCT02606578
90 Peroral Endoscopic Myotomy (POEM) for the Treatment of Esophageal Achalasia: Long vs Short Myotomy. Prospective Randomized Controlled Study Recruiting NCT03450928
91 VAC Stent: A Prospective Feasibility Study for the Treatment of Gastrointestinal Leakage Through a Combination of Covered Nitinol Stent and Negative Pressure Wound Treatment Recruiting NCT03962179
92 Assessment of the Neuro-glio-epithelial Unit (NGEU) in Biopsies Taken During Peroral Endoscopic Myotomy (POEM) for Achalasia: a Feasibility and Safety Study. Recruiting NCT04112693
93 Prospective Evaluation of the Clinical Utility of Peroral Endoscopic Myotomy (POEM) Recruiting NCT01832779
94 Ropivacaine For Post-POEM Pain Control Recruiting NCT03702647 Ropivacaine;Normal saline
95 Esophageal Cancer Risk Registry Recruiting NCT00260585
96 A Randomized, Sham and Cross-Over-Controlled Trial of Per-oral Endoscopic Pyloromyotomy (G-POEM) in Patients With Refractory Gastroparesis Recruiting NCT03356067
97 Endoscopic Clips Versus Overstich Suturing System Device for Closure of Mucosotomy After Per-oral Endoscopic Pyloromyotomy (G-POEM) Recruiting NCT03679104
98 Use of FLIP Topography to Evaluate Esophageal Symptoms in Patients With Scleroderma Recruiting NCT03270722
99 Transpyloric Stenting for Refractory Gastroparesis Prior to Gastric Per-Oral Endoscopic Myotomy: A Prospective Sham Study Recruiting NCT04287647
100 Comparison of Gastroesophageal Reflux Between Conventional Versus Oblique Fibers Sparing Endoscopic Myotomy for Achalasia Cardia - A Randomized Controlled Trial Active, not recruiting NCT04229342
101 Randomised Clinical Trial Comparing Relief of Dysphagia Between Laparoscopic Heller's Myotomy Alone Versus Laparoscopic Heller's Myotomy With Anterior Fundoplication In Achalasia Cardia-A Pilot Study Active, not recruiting NCT03438838
102 Endoscopic Versus Laparoscopic Myotomy for Treatment of Idiopathic Achalasia: A Randomized, Controlled Trial Active, not recruiting NCT01601678
103 Prospective Evaluation of Per-Oral Endoscopic Myotomy (POEM) of the Lower Esophageal Sphincter for the Treatment of Esophageal Swallowing Disorders Active, not recruiting NCT02482337
104 Institutional Outcome Data From Per-oral Plication of the Esophagus (POPE) Enrolling by invitation NCT03875365
105 Mechanisms of Weight Loss in Patients Diagnosed With Achalasia: A Prospective Observational Study Enrolling by invitation NCT03063463
106 Per-Oral Endoscopic Myotomy (POEM) for the Treatment of Achalasia, Database Repository Enrolling by invitation NCT02770859
107 Outcome Analysis of Endoluminal Therapies for Gastrointestinal Conditions Compared to Current Treatment Paradigms Enrolling by invitation NCT03123835
108 Safety and Efficacy of Antireflux Ablation Therapy (ARAT) at Esophagogastric Junction in Patients With Reflux Disease After Peroral Endoscopic Myotomy (POEM) in Achalasia Enrolling by invitation NCT04065516
109 Prospective Evaluation of the Efficacy and Safety of Submucosal Endoscopy Enrolling by invitation NCT03626350
110 Non-invasive Markers of Esophageal Function in Adults Enrolling by invitation NCT04074356
111 to Explore the Influence of Longitudinal Muscle on the Prognosis of Achalasia Patients After Peroral Endoscopic Myotomy Not yet recruiting NCT03733756
112 Assessment of Safety and Outcomes in Patients Undergoing a Standard-of-care Combined POEM-TIF Procedure Not yet recruiting NCT04052581
113 Innate Lymphoid Cells in Eosinophilic Esophagitis (French Title : Cellules Lymphoïdes innées Dans l'Oesophagite à Eosinophiles) Not yet recruiting NCT03640975
114 Correlation Between Clinical Signs and High-resolution Manometry Data in Children Not yet recruiting NCT03662490
115 Impact of Peroral Endoscopic Myotomy and Other Treatments for Oesophageal Motility Disorders on Bolus Transport and Gastro-oesophageal Reflux. The pFlow Study Not yet recruiting NCT03904004
116 Comparison of Peroral Endoscopic Myotomy (POEM) With Laparoscopic Heller Myotomy (LHM) for Treatment of Achalasia, a Retrospective Multicenter Study Terminated NCT02018705
117 Endoscopic Peroral Myotomy for Treatment of Achalasia: Multicenter Study Terminated NCT01405417
118 Volume Sensitive Multichannel Intraluminal Impedance (vMII) for the Measurement of Oesophageal Bolus Transport and Reflux Terminated NCT00604942 domperidone or esomeprazole (Conservative management);Esomeprazole 40 mg
119 Prospective Study to Assess the Diagnostic Utility of Amyl Nitrite in Patients With Suspected Achalasia Undergoing High Resolution Esophageal Manometry (HREM) Withdrawn NCT02428959 Amyl Nitrite
120 Correlation of High Resolution Esophageal Manometry With Symptoms Withdrawn NCT01202929
121 Peroral Endoscopic Myotomy Versus Botulinum Toxin Injection in the Treatment of Medical Refractory Spastic Esophageal Disorders Withdrawn NCT02663206
122 Sensorimotor Dysfunction in Achalasia Withdrawn NCT02434991

Search NIH Clinical Center for Achalasia

Genetic Tests for Achalasia

Genetic tests related to Achalasia:

# Genetic test Affiliating Genes
1 Achalasia 29

Anatomical Context for Achalasia

MalaCards organs/tissues related to Achalasia:

40
Testes, Smooth Muscle, Lung, Colon, Liver, Heart, Bone

Publications for Achalasia

Articles related to Achalasia:

(showing 6070, show less)
# Title Authors PMID Year
1
The nuclear pore complex protein ALADIN is anchored via NDC1 but not via POM121 and GP210 in the nuclear envelope. 61 54
19782045 2009
2
Triple A or Allgrove syndrome. A case report with ophthalmic abnormalities and a novel mutation in the AAAS gene. 54 61
19172511 2009
3
Axonal neuropathy with unusual pattern of amyotrophy and alacrima associated with a novel AAAS mutation p.Leu430Phe. 54 61
18628786 2008
4
Reduction of interstitial cells of Cajal (ICC) associated with neuronal nitric oxide synthase (n-NOS) in patients with achalasia. 61 54
18070236 2008
5
Association between achalasia and nitric oxide synthase gene polymorphisms. 54 61
16848803 2006
6
Intramuscular interstitial cells of Cajal associated with mast cells survive nitrergic nerves in achalasia. 61 54
16771771 2006
7
Serum from achalasia patients alters neurochemical coding in the myenteric plexus and nitric oxide mediated motor response in normal human fundus. 54 61
16105888 2006
8
Genotypic heterogeneity and clinical phenotype in triple A syndrome: a review of the NIH experience 2000-2005. 61 54
16098009 2005
9
Idiopathic achalasia is not allelic to alacrima achalasia adrenal insufficiency syndrome at the ALADIN locus. 54 61
15843079 2005
10
The diagnosis of adrenal insufficiency in a patient with Allgrove syndrome and a novel mutation in the ALADIN gene. 61 54
15690314 2005
11
Identification of the sites of expression of triple A syndrome mRNA in the rat using in situ hybridisation. 61 54
15680696 2005
12
The triple A syndrome is due to mutations in ALADIN, a novel member of the nuclear pore complex. 54 61
15666842 2004
13
Triple A syndrome: genotype-phenotype assessment. 61 54
12752575 2003
14
Achalasia of the cardia in Allgrove's (triple A) syndrome: histopathologic study of 10 cases. 61 54
12717251 2003
15
Pathophysiological significance of neuronal nitric oxide synthase in the gastrointestinal tract. 54 61
12768383 2003
16
Clinical and genetic characterization of families with triple A (Allgrove) syndrome. 61 54
12429595 2002
17
Distinct expression of splice variants of neuronal nitric oxide synthase in the human gastrointestinal tract. 54 61
10784584 2000
18
Nitric oxide synthase distribution in the enteric nervous system of children with cardiac achalasia. 61 54
9594303 1997
19
Anti-myenteric neuronal antibodies in patients with achalasia. A prospective study. 54 61
9052511 1997
20
Abnormal internal anal sphincter innervation in patients with Hirschsprung's disease and allied disorders. 54 61
8783106 1996
21
Distribution of peptide-containing nerve fibres in achalasia of the oesophagus. 61 54
8743921 1996
22
Nitric oxide in the peripheral nervous system. 61 54
7546628 1995
23
Different neurotransmitter systems are involved in the development of esophageal achalasia. 61 54
8614252 1995
24
Absence of NADPH-diaphorase activity in internal anal sphincter (IAS) achalasia. 61 54
7533833 1995
25
Transcutaneous electrical nerve stimulation decreases lower esophageal sphincter pressure in patients with achalasia. 54 61
1864193 1991
26
Enhanced platelet release reaction and increased thromboxane generation in esophageal achalasia and selective in vitro inhibition of arachidonic acid induced platelet aggregation by vasoactive intestinal peptide. 61 54
2146767 1990
27
Effect of peroral endoscopic myotomy in geriatric patients: a propensity score matching study. 61
31451922 2020
28
Needlescopic versus conventional laparoscopic Heller-Dor procedure for achalasia: a propensity score-matched analysis. 61
31901985 2020
29
EsoFLIP for esophageal dilation: proposed advantages. 61
32398561 2020
30
Robotic and per-oral endoscopic myotomy have fewer technical complications compared to laparoscopic Heller myotomy. 61
31482358 2020
31
Post-POEM reflux: who's at risk? 61
31628620 2020
32
Gastric myotomy length affects severity but not rate of post-procedure reflux: 3-year follow-up of a prospective randomized controlled trial of double-scope per-oral endoscopic myotomy (POEM) for esophageal achalasia. 61
31463720 2020
33
Two novel truncating variants of the AAAS gene causative of the triple A syndrome. 61
31939195 2020
34
Opioid-induced esophageal dysfunction. 61
32427604 2020
35
Postobesity Surgery Esophageal Dysfunction: A Combined Cross-Sectional Prevalence Study and Retrospective Analysis. 61
32558689 2020
36
Laparoscopic Heller Myotomy and Dor Fundoplication: How I Do It? 61
32311278 2020
37
Functional Luminal Imaging Probe Assessment in Postfundoplication Patients Changes Management Beyond Manometry. 61
32443039 2020
38
Layer-to-layer closure using a side channel tube and twin gasper forceps for large iatrogenic perforation during balloon dilatation for achalasia. 61
32522434 2020
39
Homozygous mutation in murine retrovirus integration site 1 gene associated with a non-syndromic form of isolated familial achalasia. 61
32573102 2020
40
The timed barium swallow and its relationship to symptoms in achalasia: Analysis of surface area and emptying rate. 61
32578341 2020
41
Upper Esophageal Sphincter Motility and Thoracic Pressure are Determinants of Pressurized Waves in Achalasia Subtypes According to the Chicago Classification. 61
32006132 2020
42
Treating children with achalasia using per-oral endoscopic myotomy (POEM): Twenty-one cases in review. 61
32197825 2020
43
Long-term risk of adult overweight and obesity among achalasia patients who underwent Heller Myotomy. 61
32557989 2020
44
Personalized Approach to the Management of Achalasia: How We Do It. 61
32558688 2020
45
Is esophageal manometry essential for the diagnosis of achalasia? Identifying patients with achalasia by the esophageal clearance method. 61
32556734 2020
46
Fair reliability of eckardt scores in achalasia and non-achalasia patients: Psychometric properties of the eckardt spanish version in a multicentric study. 61
32100424 2020
47
Multiplex immunoassays reveal increased serum cytokines and chemokines associated with the subtypes of achalasia. 61
32134545 2020
48
Intraoperative assessment of esophageal motility using FLIP during myotomy for achalasia. 61
31376012 2020
49
Factors Associated With Achalasia Treatment Outcomes: Systematic Review and Meta-Analysis. 61
31622735 2020
50
Oral Health-Related Quality of Life in People with Achalasia. 61
32545217 2020
51
Outcomes of Laparoscopic Heller Myotomy for Achalasia: 22-Year Experience. 61
32300963 2020
52
Laparoscopic Heller Myotomy and Toupet Fundoplication for Achalasia. 61
32392447 2020
53
Peroral endoscopic myotomy versus pneumatic dilation for achalasia: a systematic review and meta-analysis. 61
32516175 2020
54
Peroral endoscopic myotomy is highly effective for achalasia patients with recurrent symptoms after pneumatic dilatation. 61
32556695 2020
55
Laparoscopic Heller Myotomy and Roux-en-Y Gastric Bypass as Treatment for Patients with Achalasia and Morbid Obesity: Outcomes in a Short Series of Patients. 61
32552364 2020
56
Impedance in the evaluation of the esophagus. 61
32557676 2020
57
Anterior versus posterior peroral endoscopic myotomy: 2-years post-procedure follow-up from a randomized controlled trial. 61
32572862 2020
58
Quality of Life Following Peroral Endoscopic Myotomy for Esophageal Achalasia: A Systematic Review and Meta-Analysis. 61
32132346 2020
59
Allgrove Syndrome: A Report of New Pathological Variants in the AAAS Gene. 61
32073457 2020
60
Antireflux Surgery for Gastroesophageal Reflux Refractory to Medical Treatment After Peroral Endoscopic Myotomy. 61
32240031 2020
61
Cricopharyngeal Achalasia: Management and Associated Outcomes-A Scoping Review. 61
32571156 2020
62
Peroral endoscopic myotomy for achalasia patients with prior Heller myotomy: a systematic review and meta-analysis. 61
32522483 2020
63
Endoscopic management of gastrointestinal motility disorders - part 1: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. 61
32375192 2020
64
Clinical profile of patients presenting with dysphagia - an experience from a tertiary care center in North India. 61
32514456 2020
65
POEM for Esophageal Achalasia. 61
32315561 2020
66
Triple-A Syndrome (TAS): an in-depth overview on genetic and phenotype heterogeneity. 61
32533814 2020
67
Cardiovascular dynamics during peroral endoscopic myotomy for esophageal achalasia: a prospective observational study using non-invasive finger cuff-derived pulse wave analysis. 61
32504156 2020
68
The Malnutrition Universal Screening Tool can predict malnutrition in patients with esophageal achalasia. 61
32541242 2020
69
Anticholinergic, anti-depressant and other medication use is associated with clinically relevant oesophageal manometric abnormalities. 61
32383253 2020
70
Importance of second-look endoscopy after per-oral endoscopic myotomy for safe postoperative management. 61
32544261 2020
71
How to approach esophagogastric junction outflow obstruction? 61
32557701 2020
72
Peroral endoscopic myotomy for management of gastrointestinal motility disorder. 61
32548141 2020
73
Characterizing the proximal esophageal segment in patients with symptoms of esophageal dysmotility. 61
32485784 2020
74
Laparoscopic Heller myotomy and anterior Dor fundoplication for achalasia cardia in Malaysia: Clinical outcomes and satisfaction from four tertiary centers. 61
32423838 2020
75
Triosephosphate isomerase, carbonic anhydrase, and creatinine kinase-brain isoform are possible antigen targets in patients with achalasia. 61
31991059 2020
76
3-Dimensional Pressure Profile of the Lower Esophageal Sphincter and Crural Diaphragm in Patients with Achalasia Esophagus. 61
32437748 2020
77
Experience with Peroral Endoscopic Myotomy for Achalasia and Spastic Esophageal Motility Disorders at a Tertiary U.S. Center. 61
31744270 2020
78
Life in a world with per oral endoscopic myotomy: The ever-changing landscape in management of achalasia. 61
32387162 2020
79
Esophagogastric junction outflow obstruction: Characterization of a new entity? Clinical, manometric, and neuroimmunological description. 61
32368845 2020
80
Peroral Endoscopic Myotomy, a Well-Established, Efficacious, and Safe Treatment Option for Achalasia: Is the History of Previous Treatment a Hurdle or Not? 61
32506889 2020
81
Anesthesia for Patients Undergoing Peroral Endoscopic Myotomy Procedures: A Review of the Literature. 61
31517673 2020
82
Treatment experience with a novel 30-mm hydrostatic balloon in esophageal dysmotility: a multicenter retrospective analysis. 61
32417296 2020
83
Laparoscopic repair of late perforation following Heller myotomy due to overeating. 61
32081032 2020
84
The rhythm and rate of distension-induced esophageal contractility: A physiomarker of esophageal function. 61
31919949 2020
85
POEM for achalasia: endoscopic myotomy enters its golden age, and we are taking NOTES. 61
32327117 2020
86
Surgical VLS Therapy of Oesophageal Achalasia in Pediatric Age: Four Case Reports. 61
32523907 2020
87
Peroral endoscopic shorter versus longer myotomy for the treatment of achalasia: a comparative retrospective study. 61
32361976 2020
88
Peroral endoscopic myotomy and simultaneous endoscopic diverticuloseptotomy in a case of achalasia with diverticula. 61
31791102 2020
89
Peroral endoscopic myotomy is a safe and effective treatment modality for geriatric patients with achalasia. 61
32394115 2020
90
Short-term outcome after singular hydraulic EsoFLIP dilation in patients with achalasia: A feasibility study. 61
32391635 2020
91
Reflux symptoms and oesophageal acidification in treated achalasia patients are often not reflux related. 61
32439713 2020
92
Case report of a familial triple: a syndrome and review of the literature. 61
32481456 2020
93
Long-term outcomes of per-oral endoscopic myotomy in achalasia patients with a minimum follow-up of 4 years: a multicenter study. 61
32355884 2020
94
Clinical usefulness of esophagogastric junction distensibility measurement in patients with achalasia before and after peroral endoscopic myotomy. 61
32519955 2020
95
Peroral endoscopic myotomy for achalasia: a prospective multicenter study in Japan. 61
31759035 2020
96
Innovative Therapeutic Endoscopy in the Upper Gastrointestinal Tract: A Review of the JGES Core Sessions. 61
32415998 2020
97
Development of pseudoachalasia following magnetic sphincter augmentation (MSA) with restoration of peristalsis after endoscopic dilation. 61
32472375 2020
98
Revisional Surgery in Patients with Recurrent Dysphagia after Heller Myotomy. 61
31147973 2020
99
Determining the Safety and Effectiveness of Electrocautery Enhanced Scissors for Peroral Endoscopic Myotomy (with Video). 61
32438778 2020
100
Is Peroral Endoscopic Myotomy a Potential Therapy for Esophageal Absent Contractility? 61
32168166 2020
101
Motility Patterns Following Esophageal Pharmacologic Provocation With Amyl Nitrite or Cholecystokinin During High-Resolution Manometry Distinguish Idiopathic vs Opioid-Induced Type 3 Achalasia. 61
31419570 2020
102
Laparoscopic Heller myotomy or pneumatic dilatation in achalasia: results of a prospective, randomized study with at least a decade of follow-up. 61
32303839 2020
103
Zenker's diverticulum treated via per-oral endoscopic myotomy. 61
32313469 2020
104
Diagnostic differences in the pharmacologic response to cholecystokinin and amyl nitrite in patients with absent contractility vs type I Achalasia. 61
32350982 2020
105
Long-term outcomes of peroral endoscopic myotomy in achalasia patients with a minimum follow-up of 7 years. 61
32187047 2020
106
Therapeutic efficacy of laparoscopic Heller-Dor surgery for chest pain in patients with achalasia: a single institutional experience. 61
31586275 2020
107
Three-Dimensional High-Resolution Esophageal Manometry Study of the Esophagogastric Junction in Patients with Achalasia. 61
31541368 2020
108
Possible new endoscopic finding in patients with achalasia: "Gingko leaf sign". 61
31227944 2020
109
S-POEM in treatment of achalasia and esophageal epiphrenic diverticula - single center experience. 61
32251609 2020
110
Using Impedance Planimetry (EndoFLIP) to Evaluate Myotomy and Predict Outcomes After Surgery for Achalasia. 61
31939098 2020
111
Characteristics of a Subset of Achalasia With Normal Integrated Relaxation Pressure. 61
32102139 2020
112
Achalasia Treatment in Patients over 80 Years of Age: A Multicenter Survey. 61
31990609 2020
113
Change in body composition in patients with achalasia before and after peroral endoscopic myotomy. 61
31461542 2020
114
Long-term dysphagia resolution following POEM versus Heller myotomy for achalasia patients. 61
31292743 2020
115
Effects of Peroral Endoscopic Myotomy on Esophageal Function in the Treatment of Achalasia. 61
32274966 2020
116
Oropharyngeal swallowing functions are impaired in patients with naive-achalasia. 61
31980888 2020
117
Esophagogastric Junction Opening Parameters are Consistently Abnormal in Untreated Achalasia. 61
32289545 2020
118
Hybrid Peroral Endoscopic Myotomy for Achalasia with Prior Treatment Failure. 61
32238790 2020
119
The number and size of Lugol-voiding areas were reduced by pneumatic dilation in a patient with achalasia and esophageal cancer. 61
32280789 2020
120
Type II Achalasia as the Initial Presentation of Systemic Sclerosis. 61
32328543 2020
121
Obesity Does Not Impact Outcomes or Rates of Gastroesophageal Reflux After Peroral Endoscopic Myotomy in Achalasia. 61
31306345 2020
122
Robotic Foregut Surgery. 61
32169179 2020
123
Role of esophageal manometry and 24-h pH testing in patients with refractory reflux symptoms. 61
32388711 2020
124
Clinical and pathophysiological outcomes of the robotic-assisted Heller-Dor myotomy for achalasia: a single-center experience. 61
31230265 2020
125
Anterior versus posterior approach in peroral endoscopic myotomy (POEM): a systematic review and meta-analysis. 61
31958861 2020
126
Role of gastrointestinal endoscopy in the screening of digestive tract cancers in Europe: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. 61
32052404 2020
127
Role of Rapid Drink Challenge During Esophageal High-resolution Manometry in Predicting Outcome of Peroral Endoscopic Myotomy in Patients With Achalasia. 61
32027787 2020
128
Circumferential Heller myotomy can relieve chest pain in patients with achalasia: a prospective clinical trial. 61
32248355 2020
129
Peroral endoscopic myotomy (POEM): a comparative study between Chagasic and idiopathic achalasia. 61
32258372 2020
130
2019 Seoul Consensus on Esophageal Achalasia Guidelines. 61
32235027 2020
131
Use of a report card to evaluate outcomes of achalasia surgery: beyond the Eckardt score. 61
31286258 2020
132
The Evaluation of Esophageal Motility Using Infusion Manometry with a Trans-nasal Endoscope: A Preliminary Study. 61
31813914 2020
133
Advanced Case of Achalasia That Appeared on 68Ga-Prostate-Specific Membrane Antigen PET/CT. 61
31977457 2020
134
[Primary cricopharyngeal achalasia]. 61
30744952 2020
135
Corkscrew Esophagus in Achalasia. 61
32348647 2020
136
Endoscopic or Surgical Myotomy in Achalasia. 61
32242371 2020
137
Endoscopic or Surgical Myotomy in Achalasia. 61
32242372 2020
138
Endoscopic or Surgical Myotomy in Achalasia. 61
32242373 2020
139
Endoscopic or Surgical Myotomy in Achalasia. Reply. 61
32242374 2020
140
Quality of Life in Treating Persistent Neurogenic Dysphagia with Cricopharyngeal Myotomy. 61
31264004 2020
141
Prospective serial diagnostic study: the effects of position and provocative tests on the diagnosis of oesophageal motility disorders by high-resolution manometry. 61
32056267 2020
142
An Ivor Lewis Esophagectomy Designed to Minimize Anastomotic Complications and Optimize Conduit Function. 61
32364542 2020
143
Esophagogastric Junction Outflow Obstruction: Are We Missing Anything? 61
32301830 2020
144
Two-Stage Peroral Endoscopic Myotomy for Sigmoid-Type Achalasia. 61
31309765 2020
145
microRNA-mRNA network model in patients with achalasia. 61
31773868 2020
146
Epiphrenic diverticula: An added source of complexity in achalasia management. 61
31777144 2020
147
Cracking the Case of Achalasia-induced Syncopal Episode. 61
32328389 2020
148
The Role of Automatically Generated Chicago Classification in Delayed Achalasia Diagnosis. 61
32337311 2020
149
Secondary Achalasia in Myotonic Dystrophy May Have a Different Pathology and Management. 61
31735801 2020
150
Effect and safety of mark-guided vs standard peroral endoscopic myotomy: A retrospective case control study. 61
32206007 2020
151
Clinical analysis of surgery for type III esophageal atresia via thoracoscopy: a study of a Chinese single-center experience. 61
32228652 2020
152
Pneumatic balloon dilatation versus laparoscopic Heller myotomy for achalasia: a failed attempt at meta-analysis. 61
32180002 2020
153
Distal esophageal spasm: Update on diagnosis and management in the era of high-resolution manometry. 61
32258073 2020
154
Risk factors for gastroesophageal reflux after POEM for achalasia: a systematic review and meta-analysis. 61
32206921 2020
155
Gastroesophageal reflux disease after peroral endoscopic myotomy is unpredictable, but responsive to proton pump inhibitor therapy: a large, single-center study. 61
32208499 2020
156
Aflatoxin influences achalasia symptomatology. 61
31922241 2020
157
Evidence of GMPPA founder mutation in indigenous Guatemalan population associated with alacrima, achalasia, and mental retardation syndrome. 61
31898852 2020
158
Gastric Per Oral Pyloromyotomy for Post-Vagotomy-Induced Gastroparesis Following Esophagectomy. 61
31792900 2020
159
Poem Versus Laparoscopic Heller Myotomy in the Treatment of Esophageal Achalasia: A Case-Control Study from Two High Volume Centers Using the Propensity Score. 61
31848870 2020
160
Case report: an aortic aneurysm as cause of pseudoachalasia. 61
32143640 2020
161
Laparoscopic surgery for ventrally located epiphrenic diverticulum with esophageal achalasia. 61
32232772 2020
162
Extended Esophageal Achalasia. 61
31735799 2020
163
Long-term outcomes of per-oral endoscopic myotomy compared to laparoscopic Heller myotomy for achalasia: a single-center experience. 61
32157405 2020
164
Neck Swelling Caused by Achalasia. 61
31708546 2020
165
The Treatment of Esophageal Achalasia: At the Intersection Between Innovation and Patient's Care. 61
31895620 2020
166
An Animal Study of Implantation of an Esophageal Pacemaker Based on Per-Oral Endoscopic Myotomy Approach for Alleviation of Esophageal Peristalsis Disorders. 61
32214061 2020
167
Meglumine diatrizoate esophagogram after peroral endoscopic myotomy (POEM): identification of imaging findings associated with clinical complications and longer hospital stay. 61
32170414 2020
168
Esophageal Hypervigilance and Visceral Anxiety Are Contributors to Symptom Severity Among Patients Evaluated With High-Resolution Esophageal Manometry. 61
31990697 2020
169
Changes in high-resolution manometric diagnosis over time: implications for clinical decision-making. 61
31909786 2020
170
Doing more with less: our decade of experience with laparo-endoscopic single site Heller myotomy supports its application. 61
32180003 2020
171
Same-Session Per-Oral Endoscopic Myotomy Followed by Transoral Incisionless Fundoplication in Achalasia: Are We There Yet? 61
31922960 2020
172
Greater-curvature peroral endoscopic myotomy with diverticuloseptotomy for the treatment of achalasia in a patient with a large epiphrenic diverticulum. 61
32051916 2020
173
Functional Luminal Imaging Probe Assessment in Post-Fundoplication Patients Changes Management Beyond Manometry. 61
32049750 2020
174
Revisional Procedures for Recurrent Symptoms After Heller Myotomy and Per-Oral Endoscopic Myotomy. 61
31237487 2020
175
[Effect of electronic moxibustion on activity of parapharyngeal wall in patients with achalasia of cricopharyngeus muscle after stroke based on musculoskeletal ultrasound]. 61
32100494 2020
176
Esophagogastric Junction Outflow Obstruction: Current Approach to Diagnosis and Management. 61
32020310 2020
177
Pseudoachalasia Following Nissen Fundoplication. 61
32440524 2020
178
Upper esophageal sphincter abnormalities on high-resolution esophageal manometry and treatment response of type II achalasia. 61
32149056 2020
179
Considering the first randomized trial of peroral endoscopic myotomy versus surgical myotomy for achalasia. 61
32141831 2020
180
Two birds, one scope: peroral endoscopic myotomy as a treatment for achalasia and esophageal diverticula. 61
31991470 2020
181
European guidelines on achalasia: United European Gastroenterology and European Society of Neurogastroenterology and Motility recommendations. 61
32213062 2020
182
Peroral endoscopic myotomy for achalasia: Does myotomy position matter? 61
32036939 2020
183
Achalasia guideline: another step towards standardization of its management. 61
32213047 2020
184
[Surgical vs. endoscopic myotomy in patients with idiopathic achalasia]. 61
31996942 2020
185
Endoscopic myotomy non-inferior to surgical myotomy for idiopathic achalasia. 61
31919474 2020
186
Hematological indices as indicators of silent inflammation in achalasia patients: A cross-sectional study. 61
32118763 2020
187
A broad range of symptoms in allgrove syndrome: single center experience in Southeast Anatolia. 61
31435881 2020
188
Third Space Endoscopy: Lessons Learnt From a Decade of Submucosal Endoscopy. 61
31851106 2020
189
Per oral endoscopic myotomy as salvage therapy in patients with achalasia refractory to endoscopic or surgical therapy is technically feasible and safe: Systematic review and meta-analysis. 61
32012360 2020
190
PERORAL (POEM) OR SURGICAL MYOTOMY FOR THE TREATMENT OF ACHALASIA: A SYSTEMATIC REVIEW AND META-ANALYSIS. 61
32049194 2020
191
Applying the Functional Luminal Imaging Probe to Esophageal Disorders. 61
32040644 2020
192
Extending Myotomy Both Downward and Upward Improves the Final Outcome in Manometric Pattern III Achalasia Patients. 61
30892984 2020
193
Resection of the Gastroesophageal Junction and Roux-en-Y Reconstruction as a New Alternative for the Treatment of Recurrent Achalasia: Outcomes in a Short Series of Patients. 61
31161951 2020
194
Systematic Review and Bayesian Network Meta-Analysis Comparing Laparoscopic Heller Myotomy, Pneumatic Dilatation, and Peroral Endoscopic Myotomy for Esophageal Achalasia. 61
31364910 2020
195
Gastrointestinal Uses of Botulinum Toxin. 61
32072269 2020
196
Surgical Management of Esophageal Achalasia in Pediatrics: A Systematic Review. 61
31600801 2020
197
Eating disorder or oesophageal achalasia during adolescence: diagnostic difficulties. 61
29774515 2020
198
Stem cell factor receptor gene mutation: Achalasia, mastocytosis and gastrointestinal stromal tumors. 61
31780427 2020
199
Clinical Usefulness of Endoscopy, Barium Fluoroscopy, and Chest Computed Tomography for the Correct Diagnosis of Achalasia. 61
31588086 2020
200
Short-term safety and efficacy of peroral endoscopic myotomy for the treatment of achalasia in children. 61
31679066 2020
201
ASGE guideline on the management of achalasia. 61
31839408 2020
202
Laparoscopic Approach of the Obstruction of the Lower Third of the Esophagus in Children. 61
31721630 2020
203
Peroral endoscopic myotomy: anterior versus posterior approach: a randomized single-blinded clinical trial. 61
31408652 2020
204
Clinical efficacy of per-oral endoscopic myotomy (POEM) for spastic esophageal disorders: a systematic review and meta-analysis. 61
31073769 2020
205
Validity of the Cutoff Value for Integrated Relaxation Pressure Used in the Starlet High-Resolution Manometry System. 61
31434840 2020
206
Comment on the Article: "The Use of Rigiflex Pneumatic Balloon Dilator during Laparoscopic Heller's Myotomy in Patients with Achalasia: A Novel Technical Method and Its Surgical Outcomes". 61
32077439 2020
207
Is Z-POEM for Zenker's the same as POEM for achalasia? Or we are barking up the wrong tree? 61
31865991 2020
208
Infected esophageal subepithelial hematoma after peroral endoscopic myotomy for achalasia successfully treated with double-pigtail stent drainage. 61
31968375 2020
209
Morphologic Restoration After Peroral Endoscopic Myotomy in Sigmoid-type Achalasia. 61
31869868 2020
210
Comparison of peroral endoscopic myotomy between de-novo achalasia and achalasia with prior treatment. 61
31953735 2020
211
Peroral endoscopic myotomy with endoscopic fundoplication in a patient with idiopathic achalasia. 61
31398744 2020
212
Peroral Endoscopic Myotomy for Achalasia Combined with Submucosal Marsupialization of an Epiphrenic Diverticulum. 61
31970242 2020
213
Progression of Jackhammer Esophagus to Type III Achalasia and Improvement After Extended Myotomy. 61
31917918 2020
214
Peroral Endoscopic Myotomy versus Pneumatic Dilation in Achalasia: Dissecting the Randomized Controlled Trial. 61
31704302 2020
215
A risk-scoring system to predict clinical failure for patients with achalasia after peroral endoscopic myotomy. 61
31421076 2020
216
Efficacy of per-oral endoscopic myotomy for the treatment of non-achalasia esophageal motor disorders. 61
31932930 2020
217
Peroral Endoscopic Myotomy in a Patient with Achalasia Cardia with Prior Heller's Myotomy. 61
32095124 2020
218
Videofluoroscopic and Manometric Evaluation of Oropharyngeal and Esophageal Motility Disorders. 61
31989895 2020
219
Feeding problems and gastrointestinal diseases in Down syndrome. 61
31784293 2020
220
Multicenter collaborative retrospective evaluation of peroral endoscopic myotomy for esophageal achalasia: analysis of data from more than 1300 patients at eight facilities in Japan. 61
31183791 2020
221
PERORAL (POEM) OR SURGICAL MYOTOMY FOR THE TREATMENT OF ACHALASIA: A SYSTEMATIC REVIEW AND META-ANALYSIS. 61
32294740 2020
222
Current possibilities of minimally invasive therapy of oesophageal diverticula. 61
32545977 2020
223
Combined achalasia and cricopharyngeal achalasia in a patient with type 1 myotonic dystrophy: a case report. 61
32308942 2020
224
[Difficulties of differential diagnosis and treatment of achalasia cardia after previous hiatal hernia repair]. 61
32105260 2020
225
Gastroesophageal reflux disease after peroral endoscopic myotomy: Short-term, medium-term, and long-term results. 61
31174905 2020
226
Botox injection into the lower esophageal sphincter induces hiatal paralysis and gastroesophageal reflux. 61
31589467 2020
227
Statement for gastroesophageal reflux disease after peroral endoscopic myotomy from an international multicenter experience. 61
31559513 2020
228
Erosive Esophagitis Portends a Benign Clinical Course in the Majority of Patients. 61
31907769 2020
229
Updated Systematic Review of Achalasia, with a Focus on POEM Therapy. 61
31451984 2020
230
Application of botulinum toxin in pregnancy and its impact on female reproductive health. 61
31868020 2020
231
Acute Airway Obstruction and Cardiopulmonary Arrest due to Tracheomalacia Caused by Megaesophagus Compression Secondary to Achalasia. 61
32455044 2020
232
Pseudoachalasia: a systematic review of the literature. 61
31989338 2020
233
Achalasia Revealed by Respiratory Failure and Hemodynamic Instability. 61
32309492 2020
234
Intraoperative use of a functional lumen imaging probe during peroral endoscopic myotomy in patients with achalasia: A single-institute experience and systematic review. 61
32516319 2020
235
Achalasia- opening up the birds beak endoscopically. 61
31979867 2020
236
Hypertensive panesophageal pressurization in type II achalasia. 61
31823638 2020
237
Achalasia in a Patient with Myotonic Dystrophy. 61
31511482 2020
238
Dor versus Toupet fundoplication after Laparoscopic Heller Myotomy: Systematic review and Bayesian meta-analysis of randomized controlled trials. 61
31031056 2020
239
Laparoscopic treatment of acute abdomen due to a massive gastric dilatation. 61
31793321 2020
240
Peroral endoscopic myotomy for esophageal motility disorders. 61
31606768 2020
241
End-stage Esophageal Achalasia as Incidental Finding After Thoracic Trauma. 61
32005327 2020
242
Identification of human herpes virus 1 encoded microRNAs in biopsy samples of lower esophageal sphincter muscle during peroral endoscopic myotomy for esophageal achalasia. 61
31325192 2020
243
Clinical Symptom Presentation of Hypercontractile Peristalsis in the Era of High-Resolution Manometry: A Single-Center Experience. 61
31995802 2020
244
Atypical dysphagia with end-stage oesophageal disease 30 years post Angelchik device placement in a 72-year-old man. 61
31919056 2020
245
Esophageal motility patterns are altered in older adult patients. 61
31902552 2020
246
Minor esophageal functional disorders: are they relevant? 61
31953604 2020
247
Modified external approach to the pediatric cricopharyngeal myotomy: A case series. 61
32006861 2020
248
Endoscopic septotomy as a treatment for leaks after sleeve gastrectomy: Meeting presentations: Digestive Disease Week 2019. 61
31921987 2020
249
Esophagogastric junction outflow obstruction on manometry: Outcomes and lack of benefit from CT and EUS. 61
31523911 2019
250
Esophageal motility classification can be established at the time of endoscopy: a study evaluating real-time functional luminal imaging probe panometry. 61
31279625 2019
251
Use of multiple covered metal esophageal stents for treatment of Boerhaave syndrome in achalasia. 61
31844817 2019
252
Frequency and factors associated with malnutrition among patients with achalasia and effect of pneumatic dilation. 61
31832546 2019
253
Paravertebral Block for a Patient With Achalasia Undergoing a Peroral Endoscopic Myotomy Procedure: A Case Report. 61
31567272 2019
254
Peroral endoscopic myotomy regains anatomical structure and improves emptying for achalasia with multiple esophageal diverticula. 61
31344726 2019
255
Peroral Endoscopic Myotomy Is Effective for Patients With Achalasia and Normal Lower-Esophageal Sphincter Relaxation Pressures. 61
30153516 2019
256
Robotic versus laparoscopic approach to treat symptomatic achalasia: systematic review with meta-analysis. 61
31274153 2019
257
Esophageal Dysphagia in the Elderly. 61
31741211 2019
258
Achalasia and associated esophageal cancer risk: What lessons can we learn from the molecular analysis of Barrett's-associated adenocarcinoma? 61
31059738 2019
259
Gastrointestinal diseases among relatives of patients with esophageal atresia with or without tracheoesophageal fistula. 61
31993350 2019
260
Gastroesophageal reflux disease after peroral endoscopic myotomy: lest we forget what we already know. 61
31942638 2019
261
Novel per-oral endoscopic myotomy method preserving oblique muscle using two penetrating vessels as anatomic landmarks reduces postoperative gastroesophageal reflux. 61
31373050 2019
262
Endoscopic or Surgical Myotomy in Patients with Idiopathic Achalasia. 61
31800987 2019
263
Suprahyoid Muscle Activity in Patients with Chagasic Megaesophagus. 61
31827221 2019
264
Eosinophilic gastroenteritis presenting as achalasia cardia and responding to botulinum injection and therapy directed against eosinophilic esophagitis. 61
31950436 2019
265
Esophageal achalasia after Roux-en-Y gastric bypass for morbid obesity. 61
31691117 2019
266
Open peroral endoscopic myotomy for the treatment of achalasia: a case series of 82 cases. 61
31175357 2019
267
Etiologies and clinical characteristics of non-obstructive dysphagia in a Taiwanese population: A prospective study based on high-resolution impedance manometry. 61
30635154 2019
268
Peroral Endoscopic Myotomy Is Feasible and Safe in a Gastric Bypass Population. 61
31214967 2019
269
Functional Luminal Imaging Probe Panometry Identifies Achalasia-Type Esophagogastric Junction Outflow Obstruction. 61
31778806 2019
270
Heller myotomy versus endoscopic balloon dilatation for achalasia: A single center experience. 61
31689807 2019
271
Life-threatening acute airway obstruction induced by unsuspected achalasia. 61
30956124 2019
272
Functional lumen imaging probe in gastrointestinal motility diseases. 61
31498966 2019
273
Multicenter Evaluation of Clinical Efficacy and Safety of Per-oral Endoscopic Myotomy in Children. 61
31259787 2019
274
Outcome of peroral endoscopic myotomy in children with achalasia. 61
30671667 2019
275
Contribution of magnetic resonance imaging to the management of esophageal diseases: A systematic review. 61
31563109 2019
276
Botulinum toxin injection for internal anal sphincter achalasia after pull-through surgery in Hirschsprung disease. 61
31702647 2019
277
Anal sphincter botulinum toxin injection in children with functional anorectal and colonic disorders: A large institutional study and review of the literature focusing on complications. 61
31060739 2019
278
Distal esophageal sphincter achalasia in a Labrador retriever dog with polypoid gastric mucosal hyperplasia and pyloric stenosis. 61
31692575 2019
279
Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients. 61
31711439 2019
280
CLINICAL COURSE OF A UNIQUE CASE OF ALLGROVE SYNDROME AND CHALLENGES OF HYPOGLYCEMIA MANAGEMENT. 61
31967070 2019
281
Achalasia: treatment, current status and future advances. 61
30866609 2019
282
Anesthetic Consideration for Peroral Endoscopic Myotomy. 61
31288505 2019
283
Overlap in disease concept of functional esophageal disorders and minor esophageal motility disorders. 61
31034660 2019
284
Botulinum Toxin A Injection Using Esophageal Balloon Radiography Combined with CT Guidance for the Treatment of Cricopharyngeal Dysphagia. 61
31620859 2019
285
Safety and feasibility of performing peroral endoscopic myotomy as an outpatient procedure with same-day discharge. 61
31078571 2019
286
Per-oral endoscopic myotomy (POEM) for a sigmoid type of achalasia: short-term outcomes and changes in the esophageal angle. 61
31605214 2019
287
Treatment of achalasia by Performing Outpatient Endoscopic Myotomy (POEM). 61
31540629 2019
288
Per-oral endoscopic myotomy for achalasia: Lights and shadows. 61
31677722 2019
289
Impact of the Myotomy Extent on Gastric Side on Surgical Outcome After Heller's Cardiomotomy for Achalasia. 61
31012870 2019
290
Oesophageal achalasia diagnosed in pregnancy in a woman managed as severe hyperemesis refractory to medical management. 61
31195866 2019
291
Evaluation and Management of Premalignant Conditions of the Esophagus: A Systematic Survey of International Guidelines. 61
31403982 2019
292
Gastrointestinal dysfunction in autism displayed by altered motility and achalasia in Foxp1+/- mice. 61
31611379 2019
293
Do we need endoscopic ultrasonography for the workup of patients with esophageal motility disorder? 61
30880097 2019
294
Eosinophilic esophagitis: novel concepts regarding pathogenesis and clinical manifestations. 61
31342146 2019
295
Comparative efficacy of per-oral endoscopic myotomy and Heller myotomy in patients with achalasia: a meta-analysis. 61
31443929 2019
296
Management of Esophageal Achalasia in Quebec. 61
31636782 2019
297
Pulmonary vein isolation in a patient with achalasia and megaesophagus. 61
31700797 2019
298
[Catheter balloon dilation combined with acupuncture for cricopharyngeal achalasia after brain stem infarction: a randomized controlled trial]. 61